for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Novartis AG

NOVN.S

Latest Trade

92.69CHF

Change

-0.03(-0.03%)

Volume

2,189,706

Today's Range

92.40

 - 

93.05

52 Week Range

76.96

 - 

96.20

As of on the Virt-X ∙ Minimum 15 minute delay

Pricing

Previous Close
92.72
Open
92.47
Volume
2,189,706
3M AVG Volume
102.42
Today's High
93.05
Today's Low
92.40
52 Week High
96.20
52 Week Low
76.96
Shares Out (MIL)
2,264.61
Market Cap (MIL)
234,314.00
Forward P/E
18.22
Dividend (Yield %)
--

Next Event

Q4 2019 Novartis AG Earnings Release

Latest Developments

More

Novartis Announces EU Approval Of MS Drug Mayzent For Certain Adult Patients

Novartis to speed access to $10 bln heart drug via NHS deal

Iovance Biotherapeutics Obtains License To Develop And Commercialize A Novel IL-2 Analog

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Novartis AG

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines researches, develops, manufactures, distributes and sells patented prescription medicines to develop health outcomes for patients and healthcare providers. Sandoz develops, manufactures, distributes and sells prescription medicines, as well as pharmaceutical active substances that are not protected by valid and enforceable third-party patents. Alcon researches, develops, manufactures, distributes and sells eye care products. Alcon is a provider of eye care with product offerings in eye care devices and vision care. The Company's range of products includes pharmaceuticals and oncology medicines, generic and biosimilar medicines, and eye care devices.

Industry

Major Drugs

Contact Info

Lichtstrasse 35

+41.61.3241111

https://www.novartis.com/

Executive Leadership

Joerg Reinhardt

Independent Non-Executive Chairman of the Board

Alex Krauer

Honorary Chairman of the Board

Daniel L. Vasella

Honorary Chairman of the Board

Vasant Narasimhan

Chief Executive Officer, Member of the Executive Committee

Enrico Vanni

Independent Non-Executive Vice Chairman of the Board

Key Stats

2.15 mean rating - 27 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

48.5K

2017

49.1K

2018

51.9K

2019(E)

47.9K
EPS (USD)

2016

4.710

2017

4.860

2018

5.150

2019(E)

5.265
Price To Earnings (TTM)
30.89
Price To Sales (TTM)
4.88
Price To Book (MRQ)
4.13
Price To Cash Flow (TTM)
18.88
Total Debt To Equity (MRQ)
57.34
LT Debt To Equity (MRQ)
41.57
Return on Investment (TTM)
7.13
Return on Equity (TTM)
5.57

Latest News

Latest News

BRIEF-Novartis Announces EU Approval Of MS Drug Mayzent For Certain Adult Patients

* NOVARTIS ANNOUNCES EU APPROVAL OF MAYZENT® (SIPONIMOD) FOR ADULT PATIENTS WITH SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS (SPMS) WITH ACTIVE DISEASE

Roche aims to 'underwhelm' on SMA drug price to challenge rivals

Swiss drugmaker Roche plans to price its oral spinal muscular atrophy drug (SMA) risdiplam aggressively to challenge two of the world's most expensive medicines, Biogen's Spinraza and Novartis's gene therapy Zolgensma.

Novartis to speed access to $10 billion heart drug via NHS deal

Novartis <NOVN.S> and Britain's National Health Service (NHS) on Monday announced a pact that will clear the way for accelerated review by the country's health watchdog NICE for heart drug inclisiran, which could make it broadly available as soon as 2021.

BRIEF-Iovance Biotherapeutics Obtains License To Develop And Commercialize A Novel IL-2 Analog

* IOVANCE BIOTHERAPEUTICS OBTAINS LICENSE TO DEVELOP AND COMMERCIALIZE A NOVEL IL-2 ANALOG

BRIEF-Novartis: Ligelizumab More Effective Than Xolair At Inhibiting Immunoglobulin E Pathway

* LIGELIZUMAB (QGE031) MORE EFFECTIVE THAN XOLAIR® AT INHIBITING IMMUNOGLOBULIN E PATHWAY RESPONSIBLE FOR CHRONIC SPONTANEOUS URTICARIA

BRIEF-Novartis Completes Tender Offer For All Outstanding Shares Of The Medicines Co.

* REG-NOVARTIS COMPLETES TENDER OFFER FOR ALL OUTSTANDING SHARES OF THE MEDICINES COMPANY

Novartis, Merck and Allergan join those raising U.S. drug prices for 2020

Novartis AG, Merck & Co Inc and Allergan Plc were among companies that raised U.S. prices on more than 100 prescription medicines on Friday, bringing the tally to 445 drugs that will cost more in 2020, according to data analyzed by healthcare research firm 3 Axis Advisors.

Novartis wins Medicaid approval for new sickle cell drug in key U.S. states

Novartis AG <NOVN.S> has secured Medicaid coverage for a pricey new sickle cell disease therapy in two U.S. states just weeks after winning U.S. approval, following an early campaign to convince local officials of its value, according to a company executive and a Reuters...

BRIEF-Oxford Biomedica Announces Extension Of Commercial Supply Agreement

* OXFORD BIOMEDICA PLC - EXTENSION OF COMMERCIAL SUPPLY AGREEMENT

BRIEF-Voluntis And Novartis To Collaborate In Oncology

* COLLABORATION WITH NOVARTIS TO EVALUATE THE USE OF VOLUNTIS’ DIGITAL THERAPEUTIC PLATFORM FOR BREAST CANCER PATIENTS Source text for Eikon: Further company coverage: (Gdansk Newsroom)

BRIEF-Aduro Biotech-Notified That Novartis Removed Adu-S100 (Miw815) From Portfolio Based On Clinical Data

* ADURO BIOTECH-ON DEC 11,GOT NOTIFICATION FROM NOVARTIS THAT NOVARTIS REMOVED ADU-S100 (MIW815) FROM PORTFOLIO BASED ON CLINICAL DATA GENERATED TO DATE

Novartis drops asthma drug fevipiprant after trial failures

Swiss drugmaker Novartis on Monday said it is jettisoning what it had hoped would be a billion-dollar-selling asthma drug, fevipiprant, from its development program after the medicine failed another set of key trials.

Novartis to abandon development of asthma drug after trial failures

Swiss drugmaker Novartis is abandoning development of its drug fevipiprant in asthma after the medicine failed key trials.

BRIEF-Novartis Says It Gets Positive EMA Opinion On Macular Degeneration Treatment

* NOVARTIS RECEIVES POSITIVE CHMP OPINION FOR BEOVU® (BROLUCIZUMAB) FOR TREATMENT OF WET AMD

BRIEF-Intec Pharma Provides Update On Novartis Feasibility And Option Agreement

* INTEC PHARMA PROVIDES UPDATE ON NOVARTIS FEASIBILITY AND OPTION AGREEMENT

BRIEF-Novartis Announces FDA Filing Acceptance Of Xolair For Treatment Of Nasal Polyps

* NOVARTIS ANNOUNCES FDA FILING ACCEPTANCE OF XOLAIR® (OMALIZUMAB) FOR TREATMENT OF NASAL POLYPS

BRIEF-Novartis Kymriah Demonstrates Consistent Efficacy And Safety Outcomes In US Patients When Used In Real-World Setting

* NOVARTIS KYMRIAH® DEMONSTRATES CONSISTENT EFFICACY AND SAFETY OUTCOMES IN US PATIENTS WHEN USED IN REAL-WORLD SETTING

BRIEF-Novartis Says Phase III Data On Asthma Drug QMF149 Shows Significant Improvement

* NOVARTIS PHASE III DATA ON NEW INHALED DUAL COMBINATION QMF149 SHOW SIGNIFICANT IMPROVEMENT ACROSS KEY ASTHMA OUTCOMES VERSUS MONOTHERAPY

U.S. FDA approves generic versions of Novartis blockbuster MS treatment

The U.S. Food and Drug Administration on Thursday approved three generic versions of Swiss drugmaker Novartis AG's top-selling multiple sclerosis (MS) medicine Gilenya.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up